NSE · AHCL
Anlon Healthcare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹60 Cr with net profit ₹8 Cr — a 13.32% net margin, versus 15.49% the period before.
Shareholding
As of 2026-09-30
- Promoter52.68%
- Public46.26%
- FII1%
- DII0.06%
81,356 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.59× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Chemicals · ranked #58 of 161 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Solar Industries India Ltd. | ₹1,68,384 Cr | 74.39 | 21.93 | 29.5% | 17.7% |
| Pidilite Industries Ltd. | ₹1,60,827 Cr | 59.92 | 14.32 | 23.94% | 16.63% |
| SRF Ltd. | ₹72,932 Cr | 30.88 | 4.81 | 14.92% | 12.76% |
| Linde India Limited | ₹58,496 Cr | 118.36 | 13.32 | 11.26% | 18.08% |
| Gujarat Fluorochemicals Ltd. | ₹51,251 Cr | 75.18 | 6.1 | 7.97% | 11.43% |
| Navin Fluorine International Ltd. | ₹46,234 Cr | 50.46 | 10.36 | 20.41% | 22.4% |
| Godrej Industries Ltd. | ₹32,198 Cr | 26.32 | 2.88 | 11.1% | 5.06% |
| Himadri Speciality Chem Limited | ₹28,667 Cr | 33.54 | 5.59 | 16.65% | 15.28% |
| Deepak Nitrite Ltd. | ₹20,917 Cr | 19.53 | 3.23 | 16.4% | 10.9% |
| Aether Industries Limited | ₹20,731 Cr | 82.24 | 7.99 | 9.61% | 19.21% |
| Anlon Healthcare Limited(this company) | ₹1,435 Cr | 40.3 | 5.58 | 13.86% | 12.76% |
AI analysis
AI-generated · google/gemini-2.5-flashAnlon Healthcare Limited (AHCL) is listed in the Chemicals sector with a market capitalization of Rs 817 Cr. The company reported an EPS of 0.54 and a PE ratio of 28.46. Its book value stands at 4.33, with a Return on Equity (ROE) of 12.39% and a Return on Capital Employed (ROCE) of 16.89%. The debt-to-equity ratio is 1.46. For the quarter ended March 2026, the company recorded revenue of Rs 50.89 Cr and a net profit of Rs 10.5 Cr.
Positives
- +The Return on Capital Employed (ROCE) was 16.89%, indicating efficient use of capital.
- +Promoter shareholding in March 2026 was 52.68%, representing a majority stake.
- +No shares were pledged by promoters, with promoter pledge at 0%.
Negatives
- −The profit margin is 0%, indicating no profitability from operations based on the provided figure.
- −The debt-to-equity ratio is 1.46, which is relatively high.
- −Promoter shareholding significantly decreased from 70.26% in October 2024 to 52.68% in March 2026.
- −The company reported a negative net profit of Rs -2.49 Cr in December 2024.
- −No dividend yield was reported (0%).
Financial Performance
In the financial year ending March 2025, Anlon Healthcare Limited reported total revenue of Rs 120.45 Cr and a net profit of Rs 20.52 Cr. Quarterly revenue for March 2026 was Rs 50.89 Cr, with a net profit of Rs 10.5 Cr. This follows a previous quarter in December 2025 where revenue was Rs 35.58 Cr and net profit was Rs 5.15 Cr.
Profitability & Returns
The company's Return on Equity (ROE) is 12.39%, while the Return on Capital Employed (ROCE) is 16.89%. The earnings per share (EPS) for the most recent available annual period (Mar 2025) was Rs 6.37. The profit margin for the company is 0% based on the provided data.
Balance Sheet
Anlon Healthcare Limited has a debt-to-equity ratio of 1.46, indicating a significant reliance on debt financing. The book value per share is Rs 4.33. No further detailed balance sheet figures are available in the provided data.
Ownership & Pledges
Public shareholding stands at 42.40%. Total institutional holding is 4.92%. There are no promoter shares pledged, with promoter pledge at 0%.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.